Blinatumomab is a BiTE^® (bispecific T-cell engager) immuno-oncology therapy, which has demonstrated significant activity in patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (R/R B-ALL); however, a subset of patients relapse. Monitoring expression of cluster of differentiation (CD)19 in relapsed patients is critical to inform sequencing of subsequent therapies. The expression of CD19 in 59 pediatric patients with R/R B-ALL was analyzed on the day of diagnosis of R/R B-ALL and on days 15 and 29 of cycle 1 of blinatumomab. Most patients treated with one cycle of blinatumomab retained expression of CD19, and would therefore be eligible for subsequent anti-CD19 CAR T-cell therapy.

中文翻译：

---

博纳吐单抗治疗前后复发/难治性 B 细胞前体急性淋巴细胞白血病儿童患者的 CD19 表达

Blinatumomab 是一种 BiTE ^®（双特异性 T 细胞接合剂）免疫肿瘤疗法，已在复发或难治性 B 细胞前体急性淋巴细胞白血病 (R/R B-ALL) 患者中显示出显着的活性；然而，一部分患者复发。监测复发患者中分化簇 (CD)19 的表达对于告知后续治疗的顺序至关重要。在诊断 R/R B-ALL 当天和博纳吐单抗第 1 周期的第 15 天和第 29 天分析了 59 名 R/R B-ALL 儿科患者 CD19 的表达。大多数接受一个周期博纳吐单抗治疗的患者保留了 CD19 的表达，因此有资格接受后续的抗 CD19 CAR T 细胞治疗。